Biosimilar medications — drugs developed to be very similar, but not identical, to an FDA-approved biologic — were intended to play a vital role in increasing affordable options for patients struggling with a range of chronic conditions.
Unfortunately, those goals are not being accomplished. Pharmacy benefit managers (PBMs) are making it exceedingly difficult for physicians to provide treatments, including biosimilars. PBMs — and the insurers who often own them — are constantly changing the medications they will cover, causing unnecessary burdens for physicians while